Registry update — unassessed
Single Nuclei RNA-sequencing to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
Trial registry update: RECRUITING. No results reported in the supplied registry record.
RCTN=72Notable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Mar 18, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract provides no results, so no claims about efficacy or mechanism can be evaluated from this source material
- Without reported follow-up timepoints or outcome measures, it is unclear what endpoint was assessed
- The study compares three arms (lifestyle, senolytic drug, placebo) but the abstract does not report which intervention, if any, differed from placebo or each other
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 72
- Duration
- —
- Population
- Older obese participants
- Primary outcome
- Cellular/molecular profiling of adipose tissue and senescent cells via single nuclei RNA-sequencing (snRNA-seq)
- Effect size
- —
- Significance
- Not reported
- Journal
- Cedars-Sinai Medical Center
- Published
- Mar 18, 2026
Sources
Primary source
- Cedars-Sinai Medical Center ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq and metabolic/physiological assessments (insulin sensitivity, glucose tolerance, and β-cell function). Older obese participants will be randomized into three arms: lifestyle intervention (n=24), senolytics (n=24), or placebo (n=24).
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.